Temporary mechanical circulatory support market seen reaching $4.1 billion by 2030

The Business Research Company says the temporary mechanical circulatory support device market will grow from $2.9 billion in 2026 to $4.1 billion by 2030, fueled by rising cardiovascular disease, more minimally invasive care, and broader use of ECMO and percutaneous assist devices. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Temporary mechanical circulatory support devices help stabilize patients with acute cardiac failure, cardiogenic shock, and other high-risk heart conditions. - Demand is rising as cardiovascular disease remains widespread and more patients need short-term support during surgery, intensive care, or as a bridge to transplant or durable assist devices. - The market outlook signals where hospitals and device makers are likely to focus investment: minimally invasive systems, digital monitoring, and short-term heart support tools.

What happened: - The Business Research Company released its 2026 report on the temporary mechanical circulatory support device market. - The market is projected to grow from $2.66 billion in 2025 to $2.9 billion in 2026, a 9.0% CAGR. - The market is forecast to reach $4.1 billion by 2030, also at a 9.0% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Temporary mechanical circulatory support devices are short-term medical tools that mechanically improve blood flow and stabilize hemodynamics. - These devices are used in acute cardiac failure, cardiogenic shock, high-risk cardiac procedures, and as a bridge to heart transplantation or durable ventricular assist device implantation. - Historical growth has been tied to limited availability of temporary MCS devices, reliance on invasive open-heart surgery, high mortality rates in cardiogenic shock, greater need for acute cardiac care, and the lack of portable or wearable options. - Future growth is expected to come from biomimetic and hybrid devices, wider use of minimally invasive solutions, higher cardiac surgery volumes, growth in outpatient cardiac centers, and digital monitoring tied to intelligent hemodynamic management. - The report points to rising use of percutaneous ventricular assist devices, broader ECMO adoption, more high-risk cardiac procedures, and stronger demand for bridge-to-transplant and bridge-to-recovery therapies. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The company offers a free sample of the report. - The full report is also available online.

Between the lines: - The market is moving toward less invasive and more portable support because current use cases center on urgent care, surgery, and short-duration stabilization. - North America’s lead reflects established healthcare infrastructure and faster adoption of new cardiac technologies. - Asia-Pacific’s growth outlook suggests expanding access to cardiac care and rising procedure volumes will matter as much as the devices themselves. - GOV.UK reported in December 2024 that nearly 2.24 million adults in England had a GP-recorded diagnosis of chronic kidney disease by March 2024, up from 2.09 million the year before, adding to the population at risk of cardiovascular complications.

What’s next: - The market is likely to see more product development around percutaneous, portable, and minimally invasive systems. - Hospitals and outpatient cardiac centers are expected to expand use of short-term mechanical support as procedure volumes rise. - Digital monitoring and hemodynamic management tools may become a more important part of future device offerings.

The bottom line: - Temporary mechanical circulatory support is moving from a niche rescue therapy toward a larger, faster-growing segment of cardiac care.